MA-891 Xenograft Model Service for Breast Cancer

The MA-891 xenograft model delivers a validated in vivo translational platform designed to evaluate candidate therapies targeting aggressive, highly metastatic mammary carcinomas within a syngeneic or immunocompromised host framework. Alfa Cytology provides a comprehensive, end-to-end MA-891 xenograft model service, integrating fully authenticated cellular assets with standardized procedural and inoculation protocols to accelerate preclinical oncology drug discovery timelines.

Overview of MA-891 Xenograft Model for Breast Cancer

The MA-891 cell line is a well-characterized mouse mammary adenocarcinoma model, clinically and scientifically valued for its high tumorigenicity and propensity for spontaneous metastasis. Originally derived from a spontaneous mammary tumor in a BALB/c mouse, this model provides a critical bridge between humanized xenografts and fully immunocompetent syngeneic systems. Molecularly and phenotypically, MA-891 mimics the aggressive characteristics of advanced-stage human breast cancers, particularly regarding its hyper-proliferative growth pattern, induction of robust tumor angiogenesis, and high rate of pulmonary metastasis. These features make the MA-891 model an indispensable preclinical tool for evaluating novel anti-metastatic agents, anti-angiogenic compounds, targeted small molecules, and immunotherapeutic strategies aimed at disrupting systemic tumor progression.

When established in vivo as a model in appropriate host mice, MA-891 cells form solid, poorly differentiated tumors that faithfully preserve the intricate histopathological features and microenvironmental interactions of progressive breast malignancies.

Cell Line Information: MA-891

The MA-891 cell line maintains a stable epithelial, polygonal morphology in vitro and reliably preserves its highly proliferative and metastatic phenotype upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the MA-891 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including metastatic burden assessment and PK/PD profiling. Leveraging our expertise in highly metastatic mammary carcinoma models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of MA-891 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the MA-891 model:

• Cell Culture & Quality Control: MA-891 cells are cultivated in cell-bank-certified growth media. Quality control verification involves mandatory STR profiling (mouse-specific alignment) and mycoplasma clearance checks to guarantee phenotypic identity before inoculation.
• Host Adaptation: Standardized host mice are selected based on the specific study design (syngeneic vs. immunocompromised) and acclimated to controlled facility parameters to ensure baseline physiological stability.
• Precision Inoculation: A calibrated suspension of MA-891 cells is prepared and blended with a verified biological matrix carrier to optimize cell viability. The mixture is precisely injected in vivo via subcutaneous or orthotopic (mammary fat pad) routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 1. MA-891 Xenograft Model Construction Workflow

Case Study - MA-891 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the MA-891 model was successfully utilized to evaluate the efficacy of a novel small-molecule inhibitor targeting tumor angiogenesis and spontaneous pulmonary metastasis. Our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms under optimized modeling conditions, allowing for an unobstructed and definitive assessment of therapeutic efficacy. The in vivo study successfully demonstrated significant, dose-dependent primary tumor growth inhibition and a marked reduction in metastatic lung nodules in the treatment group compared to the vehicle control.

Our Advantages

Choosing the right partner for your highly metastatic mammary carcinoma research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified tumor cell lines with stable, traceable genetic hallmarks.
• Technical Consistency: Optimized inoculation protocols ensuring uniform tumor growth and minimizing variance.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research standards.

Contact Us

Are you looking to advance your therapeutic pipeline against highly metastatic mammary carcinomas using the robust MA-891 platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.